NEW YORK (GenomeWeb News) — Ocimum Biosolutions has acquired the biomolecular synthesis segment of Dutch company Isogen Life Sciences, Ocimum said today.
Ocimum CEO Anuradha Acharya said the acquisition is “a significant step towards becoming a global oligo player,” and said the company will continue to look for strategic targets to expand its oligo-production capacity.
Acharya added that the deal will help the company “become a more integrated genomics services provider” with delivery points in Indianapolis, Indiana; IJsselstein, the Netherland; and Hyderabad, India.
Financial terms of the deal were not released.